Genatom Inc.

Genatom Inc. specializes in innovative genetic analysis and diagnostic solutions, addressing complex challenges in healthcare and research sectors, with a focus on delivering precise and efficient genetic testing services. Genatom Inc. operates in the genetic testing industry, providing specialized solutions for healthcare professionals and researchers.

The company was acquired by Manhattan Physicians Laboratories, a portfolio company of Trevi Health Ventures, in May 2008, marking a significant pivot in its business operations. Genatom is headquartered in Roseland, US, where it continues to serve a diverse clientele in the genetic diagnostics field. The founder’s prior experience in the biotech sector has been instrumental in shaping the company’s strategic direction. Genatom Inc.

primarily provides advanced genetic testing solutions aimed at healthcare practitioners and researchers. Their core offerings include a range of genetic analysis services that assist in diagnosing genetic disorders and facilitate personalized medicine approaches. The company’s services are designed to meet the needs of various stakeholders in the healthcare industry, ensuring accuracy and reliability in genetic testing. Genatom operates in multiple markets, supporting clients in their pursuit of effective genetic diagnostics.

Genatom Inc. generates revenue predominantly through its genetic testing services, which are offered on a subscription basis or as standalone tests. Clients pay for these services, allowing them to access high-quality genetic analysis tailored to their specific needs. The revenue model includes direct transactions with healthcare providers and research institutions, ensuring a streamlined approach to accessing genetic diagnostics.

Looking to the future, Genatom Inc. plans to expand its portfolio with new genetic testing products aimed at enhancing diagnostic accuracy. The company is targeting expansion into international markets, with specific plans to enter Europe and Asia by the end of 2025. Recent funding from the acquisition deal in May 2008 will support these initiatives, allowing Genatom to enhance its research and development capabilities and broaden its market reach.